Kiromic Biopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kiromic Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Kiromic Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$7.44M, a 77.3% decline year-over-year.
  • Kiromic Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$25.1M, a 7.6% decline year-over-year.
  • Kiromic Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$20.9M, a 39.7% increase from 2022.
  • Kiromic Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$34.7M, a 35.7% decline from 2021.
  • Kiromic Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$25.6M, a 33.3% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$25.1M -$7.44M -$3.24M -77.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 -$21.9M -$6.83M -$61K -0.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-08
Q1 2024 -$21.8M -$6.15M -$847K -16% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-08
Q4 2023 -$20.9M -$4.69M +$2.38M +33.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 -$23.3M -$4.19M +$7.67M +64.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 -$31M -$6.76M +$1.67M +19.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-08
Q1 2023 -$32.7M -$5.3M +$2.07M +28.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-08
Q4 2022 -$34.7M -$7.07M +$3.57M +33.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 -$38.3M -$11.9M -$5.74M -93.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$32.6M -$8.44M -$3.46M -69.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$29.1M -$7.37M -$3.51M -91.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$25.6M -$10.6M -$7.07M -198% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 -$18.5M -$6.12M -$3.71M -154% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$14.8M -$4.97M +$6.39M +56.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$21.2M -$3.85M -$2M -108% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$19.2M -$3.56M -$1.4M -64.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-04-08
Q3 2020 -$17.8M -$2.42M -$1.53M -172% Jul 1, 2020 Sep 30, 2020 10-Q 2022-03-11
Q2 2020 -$16.3M -$11.4M -$11.1M -3954% Apr 1, 2020 Jun 30, 2020 10-Q 2022-03-11
Q1 2020 -$5.19M -$1.85M -$1.46M -374% Jan 1, 2020 Mar 31, 2020 10-Q 2022-03-11
Q4 2019 -$3.73M -$2.17M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$887K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-30
Q2 2019 -$280K Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-30
Q1 2019 -$391K Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.